Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain-Reference-Cited by-同舟云学术

Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain

Published:2022-12-31 Issue:5 Volume:25 Page:1463-1471
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Munoz Paula^ORCID,Corral Sara,Martínez-Regueira Fernando,Paz Alejandro,Muñoz-Madero Vicente,Mena Antonio,Cabañas Jacobo,Rivas Sonia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12094-022-03049-6.pdf

Reference32 articles.

1. Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf MM, Digiovanna MP, et al. Use of neoadjuvant chemotherapy for patients with stage i to III breast cancer in the United States. Cancer. 2015;121(15):2544–52.

2. Vugts G, Maaskant-Braat AJG, Nieuwenhuijzen GAP, Roumen RMH, Luiten EJT, Voogd AC. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. Popul Based Study Breast J. 2016;22(3):316–21.

3. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304–11.

4. Lim B. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: Findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Vol. 26, Breast Diseases. Academic Press Inc.; 2015. p. 249–50.

5. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884–9.